BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Toctino alitretinoin: Completed Phase III enrollment

Basilea disclosed in its 2010 earnings that it completed enrollment of 600 patients who do not respond to topical steroids in the double-blind, U.S. Phase III HANDEL trial comparing oral...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >